Apremilast for biologic-naïve, peripheral psoriatic arthritis, including patients with early disease: results from the aproach observational prospective study

HIGHLIGHTS

• who: Petros P. Sfikakis from the biologic-nau00efve patients, while improvements were noted as early as after , weeks of treatment [10, ] and sustained for up to , years [18]To complement data derived from clinical trials, the APROACH study aimed to generate real-world evidence on the effect of apremilast across various clinical and patientreported outcomes (PROs) in a representative sample of biologic-nau00efve patients with early PsA treated under reallife conditions in Greece have published the research work: Apremilast for biologic-nau00efve, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective study . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.